age recommendation for prevnar
In addition, no more than 2 doses of PPSV23 should be given prior to age 65. Refer to the CDC’s specific recommendations and dosing charts for more information. Adults who are 65 or older who smoke or have chronic conditions such as alcoholism, asthma, diabetes, or heart disease should receive PPSV23 only. however we want providers to be aware of all important vaccine updates regardless of the age indication. PCV13 or PPSV23, should receive a dose of PCV13 first, followed by a dose of PPSV23 at least 8 weeks later. Subsequent doses of PPSV23 should follow current PPSV23 recommendation for adults at high risk. The Maine Immunization Program (MIP) supplies vaccine at no charge to children 0 through 18 years old, however we want providers to be aware of all important vaccine updates regardless of the age indication. ACIP recommendations for PCV13 and PPSV23 Use: 1 PCV13: Pneumococcal conjugate vaccine for all infants and children, and adults 19 years and older at high risk for disease (Spanish) (PDF - 290KB)  PPSV23: Pneumococcal polysaccharide vaccine for all adults 65 years and older and those 2 years of age and older at high risk for disease (Spanish) (PDF - 297KB) Published Online: Monday, April 15, 2013. The CDC’s 2013 immunization schedules include several new recommendations regarding which patient groups should receive the various pneumococcal vaccines. One dose of PCV13 is recommended for children 6 through 18 years old and adults 19 through 64 years old with the following medical conditions that put them at increased risk for pneumococcal disease: Cerebrospinal fluid (CSF) leaks (leak in fluid around the brain and spine) The FDA has approved PCV13 for all adults 50 years of age or older, but in this age group ACIP recommends the vaccine only for those at elevated risk for pneumococcal disease. In addition, ACIP recommends that at-risk patients receive both PCV13 and PPSV23. ACIP recommends the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults older than 65 years and for those younger than 65 who are at high risk for pneumococcal disease or complications from pneumococcal disease. Recommendations for Pneumococcal Vaccine Use in Children and Teens, please visit: www.immunize.org/catg.d/p2016.pdf. Please remember that the MIP only provides vaccine to children ages 0 through 18 years old and this. information is for your guidance only. On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent. pneumococcal conjugate vaccine (PCV13; Prevnar) for adults aged ≥ 19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants.
Aged ≥ 19 years